Equities analysts expect Xeris Pharmaceuticals Inc (NASDAQ:XERS) to report sales of $2.17 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Xeris Pharmaceuticals’ earnings, with estimates ranging from $1.80 million to $2.70 million. Xeris Pharmaceuticals reported sales of $310,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 600%. The company is expected to issue its next earnings report on Tuesday, August 4th.
On average, analysts expect that Xeris Pharmaceuticals will report full-year sales of $15.01 million for the current fiscal year, with estimates ranging from $12.30 million to $18.10 million. For the next financial year, analysts forecast that the firm will report sales of $59.43 million, with estimates ranging from $54.10 million to $64.40 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Xeris Pharmaceuticals.
Xeris Pharmaceuticals (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.03. Xeris Pharmaceuticals had a negative net margin of 3,100.00% and a negative return on equity of 323.82%. The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.82 million.
NASDAQ XERS traded down $0.34 on Friday, hitting $4.77. 582,700 shares of the stock were exchanged, compared to its average volume of 621,265. The company has a quick ratio of 4.72, a current ratio of 4.82 and a debt-to-equity ratio of 2.16. Xeris Pharmaceuticals has a fifty-two week low of $1.42 and a fifty-two week high of $12.94. The company has a market cap of $192.08 million, a PE ratio of -1.02 and a beta of 2.12. The company has a 50-day moving average price of $3.27 and a 200-day moving average price of $4.91.
In related news, insider John Patrick Shannon, Jr. bought 22,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $3.55 per share, for a total transaction of $78,100.00. Following the acquisition, the insider now owns 117,493 shares in the company, valued at approximately $417,100.15. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Paul R. Edick bought 33,000 shares of the stock in a transaction dated Friday, May 8th. The stock was bought at an average price of $3.54 per share, with a total value of $116,820.00. Following the acquisition, the insider now owns 95,493 shares in the company, valued at approximately $338,045.22. The disclosure for this purchase can be found here. Corporate insiders own 5.95% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. FMR LLC boosted its stake in Xeris Pharmaceuticals by 29.9% during the 1st quarter. FMR LLC now owns 2,963,018 shares of the company’s stock worth $29,749,000 after purchasing an additional 682,050 shares during the period. ArrowMark Colorado Holdings LLC boosted its stake in Xeris Pharmaceuticals by 21.4% during the 1st quarter. ArrowMark Colorado Holdings LLC now owns 2,341,902 shares of the company’s stock worth $4,567,000 after purchasing an additional 413,594 shares during the period. BlackRock Inc. boosted its stake in Xeris Pharmaceuticals by 6.4% during the 1st quarter. BlackRock Inc. now owns 2,336,418 shares of the company’s stock worth $4,555,000 after purchasing an additional 139,671 shares during the period. Citigroup Inc. boosted its stake in Xeris Pharmaceuticals by 66,662.9% during the 4th quarter. Citigroup Inc. now owns 2,201,839 shares of the company’s stock worth $15,523,000 after purchasing an additional 2,198,541 shares during the period. Finally, State Street Corp boosted its stake in Xeris Pharmaceuticals by 8.3% during the 1st quarter. State Street Corp now owns 542,031 shares of the company’s stock worth $1,057,000 after purchasing an additional 41,630 shares during the period. Hedge funds and other institutional investors own 62.48% of the company’s stock.
Xeris Pharmaceuticals Company Profile
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Recommended Story: What is a Special Dividend?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.